OverviewChartNewsTraderScreen

HSBC Call 3900 TDXP 18.09.2024/  DE000HS147B9  /

Frankfurt Zert./HSBC
2024-08-01  10:50:31 AM Chg.0.000 Bid2024-08-01 Ask2024-08-01 Underlying Strike price Expiration date Option type
0.001EUR 0.00% 0.001
Bid Size: 10,000		 0.031
Ask Size: 10,000		 TECDAX 3,900.00 EUR 2024-09-18 Call
GlobeNewswire 05-14 CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
GlobeNewswire 2018-06-12 Software AG acquires Technology Scale-up TrendMiner for analysis and visualization of time series da...
GlobeNewswire 2016-12-20 Medigene announces outlicensing of AAVLP technology
GlobeNewswire 2016-12-13 MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or...
GlobeNewswire 2016-12-06 Medigene AG to be included in TecDAX Index
GlobeNewswire 2016-12-06 MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in NHL and CLL at ASH 201...
GlobeNewswire 2016-12-06 MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016
GlobeNewswire 2016-11-28 MorphoSys Announces That Its Licensee Janssen Has Submitted a Marketing Authorisation Application Fo...
GlobeNewswire 2016-11-17 MorphoSys Announces That Its Licensee Janssen Has Submitted Biologics License Application For Guselk...
GlobeNewswire 2016-11-15 MorphoSys Raises EUR 115 million in Private Placement
GlobeNewswire 2016-11-15 Ad hoc: MorphoSys Raises EUR 115 million in Private Placement
GlobeNewswire 2016-11-15 MorphoSys to Raise Capital via a Private Placement of New Shares
GlobeNewswire 2016-11-15 Ad hoc: MorphoSys to Raise Capital via a Private Placement of New Shares
GlobeNewswire 2016-11-15 MorphoSys Announces That Its Licensee Janssen Has Presented Positive Clinical Data of Guselkumab in ...
GlobeNewswire 2016-11-14 MorphoSys to Present at Upcoming Investor Conferences
GlobeNewswire 2016-11-08 Anke Linnartz joins MorphoSys as Head of Corporate Communications and Investor Relations
GlobeNewswire 2016-11-07 MorphoSys AG Reports Results for the First Nine Months of 2016
GlobeNewswire 2016-11-03 MorphoSys Announces Presentations of Clinical Data at Upcoming American Society of Hematology (ASH) ...
GlobeNewswire 2016-11-02 MorphoSys and LEO Pharma Enter into Strategic Alliance to Develop Therapeutic Antibodies in Dermatol...
GlobeNewswire 2016-10-28 MorphoSys to Host Q3 2016 Conference Call on November 7, 2016
GlobeNewswire 2016-10-20 MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial with Novel Cancer Antibody
GlobeNewswire 2016-10-17 MorphoSys Presents Updated Clinical Results for MOR202 at Medical Conference
GlobeNewswire 2016-10-01 MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Gusel...
GlobeNewswire 2016-10-01 Ad hoc: MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study ...
GlobeNewswire 2016-09-29 MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis